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Introduction: Breast cancer cells display preferences for specific metastatic sites including the bone, lung and liver.
Metastasis is a complex process that relies, in part, on interactions between disseminated cancer cells and resident/
infiltrating stromal cells that constitute the metastatic microenvironment. Distinct immune infiltrates can either impair
the metastatic process or conversely, assist in the seeding, colonization and growth of disseminated cancer cells.
Methods: Using in vivo selection approaches, we previously isolated 4T1-derived breast cancer cells that preferentially
metastasize to these organs and tissues. In this study, we examined whether the propensity of breast cancer cells to
metastasize to the lung, liver or bone is associated with and dependent on distinct patterns of immune cell infiltration.
Immunohistocytochemistry and immunohistofluorescence approaches were used to quantify innate immune cell
infiltrates within distinct metastases and depletion of Gr1+ (Ly-6C and Ly-6G) or specifically Ly-6G+ cells was performed
to functionally interrogate the role of Ly-6G+ infiltrates in promoting metastasis to these organs.
Results: We show that T lymphocytes (CD3+), myeloid-derived (Gr-1+) cells and neutrophils (Ly-6G+ or NE+) exhibit the
most pronounced recruitment in lung and liver metastases, with markedly less recruitment within bone metastatic
lesions. Interestingly, these infiltrating cell populations display different patterns of localization within soft tissue
metastases. T lymphocytes and granulocytic immune infiltrates are localized around the periphery of liver metastases
whereas they were dispersed throughout the lung metastases. Furthermore, Gr-1+ cell-depletion studies demonstrate
that infiltrating myeloid-derived cells are essential for the formation of breast cancer liver metastases but dispensable
for metastasis to the lung and bone. A specific role for the granulocytic component of the innate immune infiltrate
was revealed through Ly-6G+ cell-depletion experiments, which resulted in significantly impaired formation of liver
metastases. Finally, we demonstrate that the CD11b+/Ly-6G+ neutrophils that infiltrate and surround the liver
metastases are polarized toward an N2 phenotype, which have previously been shown to enhance tumor growth and
metastasis.
Conclusions: Our results demonstrate that the liver-metastatic potential of breast cancer cells is heavily reliant on
interactions with infiltrating Ly-6G+ cells within the liver microenvironment.* Correspondence: peter.siegel@mcgill.ca
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Communication between the tumor and surrounding
stromal cells is a critical determinant governing the abil-
ity of cancer cells to metastasize to specific organs. The
tumor microenvironment consists not only of extracellu-
lar matrix proteins, resident fibroblasts and endothelial
cells, but also infiltrating innate (macrophages, neutro-
phils, myeloid-derived suppressor cells or natural killer
cells) and adaptive (B and T lymphocytes) immune cells
[1]. Leukocyte infiltrates are present in the majority of
solid tumors; however, the functional roles and clinical
consequences of these immune cell infiltrates are com-
plex [2]. In some circumstances, the ability of inflamma-
tory cells to destroy tumor cells has been associated with
better prognosis [3,4]. In contrast, numerous studies
have shown that inflammation can also contribute to the
establishment of primary tumors and subsequent metas-
tasis by allowing tumor cells to escape and/or actively
suppress anti-tumor immune responses [2,5,6]. While
cancer-related inflammation has mostly been studied in
the context of primary tumor growth, it is now accepted
that inflammatory cells and secreted mediators are also
involved in the migration, invasion and metastasis of
malignant cells [2].
Tumor-associated macrophages (TAMs) and myeloid-
derived suppressor cells (MDSCs) are well-characterized
infiltrating innate cell populations that augment breast
cancer metastasis [7], in part, through their ability to
stimulate tumor angiogenesis and suppress anti-tumor
immunity [8,9]. Infiltration of MDSCs, which are defined
as CD11b/Gr-1 double-positive myeloid cells, into the
primary tumor and metastatic sites is often associated
with poor prognosis in breast cancer patients [10,11].
MDSCs suppress both innate and adaptive immune re-
sponses resulting in diminished effector T cell functions
[6,12]. In addition, MDSCs also promote the activation
and expansion of regulatory T cells to mediate immuno-
suppression [13]. MDSC accumulation at distant meta-
static sites, which contributes to the establishment of a
pre-metastatic niche, has also been reported to enhance
metastatic efficiency [14]. Thus, the pre-metastatic niche
may provide ‘privileged sites’ for tumor cells to adhere and
successfully colonize different organs and tissues [15,16].
Neutrophils are garnering attention as important modu-
lators of cancer progression [17-20]. Like TAMs, tumor-
associated neutrophils (TANs) may exist in different states
of activation/differentiation [21]. TANs can adopt either
an anti-tumorigenic (N1) or a pro-tumorigenic (N2)
phenotype. Thus, N1-polarized neutrophils have the po-
tential to kill cancer cells and inhibit tumor growth
[22-24] as well as coordinate adaptive immune responses
through interactions with dendritic cells [25]. In contrast,
N2 neutrophils may support tumor growth by producing
pro-angiogenic factors and matrix-degrading enzymes,suppress anti-tumor immune responses and facilitate me-
tastasis [21,26-28]. Thus, infiltrating innate immune cell
populations, such as TAMs, MDSCs or TANs, can play
complex roles during cancer initiation and progression to
metastasis. To understand how these cell populations in-
fluence general and/or organ-specific breast cancer metas-
tasis, we employed 4T1 breast cancer cell populations
isolated from primary mammary tumors, as well as those
explanted from bone, lung or liver metastases. Our data
reveal that breast cancer cells derived from different meta-
static sites are characterized by unique and overlapping
patterns of chemokine expression and secretion. Interest-
ingly, liver-metastatic breast cancer cells display high
levels of chemokines that recruit a variety of innate im-
mune cell populations. Using antibody-mediated depletion
of Ly-6G+ cells in immune-competent mice, we uncover a
pro-metastatic function for this specific component of the
innate immune infiltrate, which is required for the estab-
lishment of liver metastases but dispensable for bone and
lung metastases.Methods
Cell culture and transfections
The 4T1 cell line was obtained from the American Type
Culture Collection and cultured as previously described
[29]. The isolation of 4T1-derived cells explanted from
primary tumors (148, 152 or 154), 4T1-derived liver-
aggressive cell populations (2776, 2792 and 2869), 4T1-
derived lung-aggressive cell populations (526, 533 and
537) and 4T1-derived bone-aggressive cell populations
(590, 592 and 593) were described previously [29-31].RNA amplification, labeling and hybridization to Agilent
microarrays
RNA was extracted from 4T1 parental and individual
in vivo selected metastatic subpopulations, purified total
RNA was subjected to amplification and hybridized to
44 K whole mouse genome microarray gene expression
chips (Agilent Technologies, Santa Clara, CA, USA) as
described previously [30].Gene expression analysis
Microarray expression data were normalized and ana-
lyzed using GeneSpring software (V7.3, Agilent Tech-
nologies). Each group (parental cell line and the explants
derived from mammary fat pad, bone, lung and liver me-
tastasis) was individually compared to all the other
groups. A two-fold change cutoff was determined and
differentially expressed genes were selected using a non-
parametric test coupled with a false discovery rate of
0.05. The microarray data can be accessed through the
GEO repository (ID GSE62598).
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Analysis of differentially expressed genes was performed
in the context of gene ontology, canonical pathways and
molecular networks using the Ingenuity Pathways Ana-
lysis (IPA, Ingenuity Systems™, Qiagen, Redwood City,
CA, USA). The differentially expressed genes were com-
pared to genetic categories in the IPA database, and
ranked according to P values.
Chemokine array
To detect and quantify chemokines secreted by each cell
population, serum-free conditioned media (CM) was
collected from cells cultured for 48 h and applied to a
chemokine (mouse) quantitative antibody array (Abnova
Corp., Taipai, Taiwan, cat#AA0118) following the manu-
facturer’s protocol. Array scans were acquired with a
GenePix 4000B scanner (Molecular Devices, Sunnyvale,
CA, USA) at a 5 uM/pixel resolution and features were
extracted with the GenePix 6.1 software. The experiment
was performed in duplicate.
Immunohistocytochemistry
For CD3 staining, tissue sections were stained with the
Benchmark XT autostainer (Ventana Medical Systems,
Inc., Tucson, AZ, USA). Antigen retrieval was performed
using Cell Conditioning 1 (Ventana Medical Systems, Inc.,
cat#950-124) for 60 minutes, following the manufacturer’s
instructions. Pre-diluted antibody (CD3: 1:100, Abcam,
Cambridge, MA, USA, cat#ab16669) was manually added
to the slides and incubated at 37°C for 60 minutes. Re-
actions were performed using the iView DAB detection
kit without secondary antibody (Ventana Medical Sys-
tems, Inc., cat#760-093), where pre-diluted anti-rabbit
secondary antibody (1:300; Santa Cruz Biotechnology,
Dallas, TX, USA) was automatically dispensed. Counter-
staining was achieved with hematoxylin and bluing re-
agent (Ventana Medical Systems, Inc., cat#760-2021 and
cat#760-2037).
For Ly-6G or neutrophil elastase (NE) staining, un-
stained sections (4 μm) were subjected to antigen re-
trieval in 10 mM citrate buffer (pH 6.0) for 20 minutes
at sub-boiling temperatures. Slides were incubated over-
night at 4°C with a rabbit anti-Ly-6G antibody (clone
1A8; 1:200 dilution, BD Pharmingen, San Jose, CA,
USA, cat#551459) or with a rabbit anti-neutrophil elas-
tase antibody (1:200 dilution, Abcam, cat#ab68672). Fol-
lowing incubation with the primary antibody, secondary
biotin-conjugated antibodies were applied for 45 minutes.
After washing with phosphate-buffered saline (PBS),
slides were developed with diaminobenzidine (Dako,
Glostrup, Denmark) as the chromogen and counter-
stained with Harris hematoxylin. All slides were scanned
using a Scanscope XT digital slide scanner (Aperio,
Vista, CA, USA). Scans were quantified by analyzingpositive staining with Imagescope software (Aperio) using
the positive pixel count algorithm. In all analyses, only
moderate (+2) and strong (+3) staining was considered as
positive pixels. For all staining, data are expressed as a ra-
tio of positive pixels over the total pixels per field.
Immunofluorescence
Unstained sections (4 μm) were blocked in 1% bovine
serum albumin (BSA) with 2% horse serum and 0.05%
Tween-20 for 30 minutes. Slides were incubated overnight
at 4°C with a goat anti-S100a8 antibody (1:50 dilution,
Santa Cruz Biotechnology, cat#sc-8112) and with a rabbit
anti-NE antibody (1:50 dilution, Abcam, cat#ab68672).
Following incubation with the primary antibody, sections
were incubated with Alexa Fluor 555-conjugated donkey
anti-goat (cat#A-21432; Molecular Probes, Eugene, OR,
USA) and Alexa Fluor 647-conjugated donkey anti-rabbit
(Molecular Probes, cat#A-31573) secondary antibodies.
Nuclei were counterstained with 4′, 6′-diamidino-2-
phenylindole (DAPI), and images were taken (63X) using
a Zeiss LSM 710 confocal on an Axio Observer full-
motorized inverted microscope (Carl Zeiss Microscopy,
Jena, Germany). Images were analyzed with MetaXpress
software (Molecular Devices, Sunnyvale, CA, USA). Data
is expressed as a percentage of cells double positive for
S100a8 and NE over the total number of S100a8-
positive cells. Two independent reviewers scored the co-
localization of these markers (BEH, CET).
Finally, OCT-embedded livers were sectioned (10 μm)
and fixed in methanol for 10 minutes. The sections were
blocked with 2% BSA and 1% normal horse serum (Vector
Laboratories, Burlingame, CA, USA, cat#S-2000) and
subsequently incubated overnight at 4°C with a primary
antibody directed against Ly-6G (clone 1A8; 1:100 dilu-
tion, BD Pharmingen, cat#561236), CD11b (clone M1/70,
1:100 dilution, eBioscience, San Diego, CA, USA cat#53-
0112) and MMP9 (1:100 dilution, Abcam, cat#ab38898).
Following incubation with the indicated primary anti-
bodies, Alexa Fluor 555-conjugated donkey anti-rabbit
(Molecular Probes, cat#A-31572) secondary antibodies
were applied to each section. Nuclei were counterstained
with DAPI, and images were taken (63X) using a Zeiss
LSM 710 confocal on an Axio Observer full-motorized
inverted microscope (Carl Zeiss Microscopy). Images were
analyzed with MetaXpress software (Molecular Devices)
and the data expressed as a percentage of Ly-6G+CD11b+
MMP9+ triple-positive cells (N2-polarized neutrophils)
over the total number of Ly-6G+CD11b+ double-positive
cells (neutrophils). Three independent reviewers scored
the co-localization of these markers (VO, BEH and ST).
Experimental metastasis assays
Experimental liver metastasis assays (1 × 105 cells; splenic
injection) and experimental lung metastasis assays (5 ×
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described [30,32]. Tumor burden in the liver (left cardiac
lobe) and lungs was quantified as previously reported [30].
The tumor area/tissue area was quantified using Image-
scope software (Aperio). Experimental bone metastasis as-
says (1 × 105 cells; left cardiac ventricle injection) as well
as X-ray micro-computed tomography (μCT) imaging was
conducted as previously described [33]. All mice were
sacrificed two weeks following injection. The mice were
housed in facilities managed by the McGill University
Animal Resources Centre and all animal experiments were
conducted under a McGill University-approved Animal
Use Protocol (AUP #5129), which was reviewed by the Fa-
cility Animal Care Committee for the Faculty of Medicine
(Committee A). All projects involving live animals were
subjected to peer review for scientific merit, in accordance
with guidelines established by the Canadian Council on
Animal Care.
Antibody-mediated depletion experiments
To deplete Gr-1+ cells in vivo, purified anti-Ly-6G/Ly-
6C rat monoclonal antibody (mAb) (clone RB6-8C5,
AbLab, University of British Columbia, BC, Canada) or
control isotype immunoglobulin G (IgG) were adminis-
tered to cohorts of mice. In all cases, mice were treated
by intraperitoneal (i.p.) injection (1.5 μg/g) of purified
antibodies. Mice were first treated 24 h prior to tumor
cell injection and every 72 h thereafter. Differential
leukocyte counts were performed at the completion of
each experiment and revealed greater than 90% deple-
tion of peripheral blood neutrophils using these treat-
ment regimes.
To specifically deplete Ly-6G+ cells in vivo, purified
anti-Ly-6G rat mAb (clone 1A8, BioXcell, West Lebanon,
NH, USA) or control isotype IgG (clone 2A3, BioXcell)
were administered to cohorts of mice. Mice were treated
by i.p. injection (5.5 μg/g) of purified antibodies as indi-
cated. Briefly, mice were first treated 24 h prior to tumor
cell injection and every 48 h thereafter. Differential
leukocyte counts were performed at the completion of the
experiment and revealed greater than 94% depletion of
peripheral blood neutrophils using these treatment re-
gimes. At the experimental endpoint, immunohistochem-
ical staining for Ly-6G revealed up to 65% depletion of
liver-infiltrating neutrophils in mice treated with the 1A8
antibody versus the 2A3 isotype control. Quantification
of Ly-6G staining was performed as described above
(Immunohistocytochemistry).
CD11b+/Ly-6G+ cell isolation
Seven days or 14 days following splenic injection of the
breast cancer cells, CD11b+/Ly-6G+ cells were isolated
from the metastasis-bearing livers. Livers were first per-
fused with perfusion medium (Gibco, Waltham, MA,USA, cat#17701-038) for 10 minutes at 5 ml/min. Fol-
lowing perfusion, livers were minced and dissociated for
1 h in a mix of collagenase A, collagenase B and hyal-
uronidase (2 mg/ml each, Roche, Basel, Switzerland,
cat#11088793001 and 11088031001; Sigma-Aldrich, St
Louis, MO, USA, cat#H3884).
To purify CD11b+/Ly-6G+ cells [34,35], cells were
blocked in 2.4G2 (1:10 dilution) for 30 minutes and then
incubated for 30 minutes, in the dark, with an antibody
cocktail containing anti-mouse CD11b-APC (1:10000 di-
lution, eBioscience, clone M1/70, cat#17-0112-82) and
rat anti-mouse Ly-6G-PerCP-Cy5.5 (1:1000 dilution, BD
Biosciences, San Jose, CA, USA, clone 1A8, cat#560602).
Subsequently, cells were washed once with PBS and then
incubated with Live/Dead stain (1:1000 dilution) for
30 minutes. Cells were then washed once with PBS and
resuspended in fluorescence-activated cell sorting (FACS)
buffer (PBS complemented with 2% fetal bovine serum
(FBS)). Samples were read on the BD FACS Canto (BD
Biosciences).
RNA isolation and real-time RT-PCR
Total RNA from isolated CD11b+/Ly-6G+ neutrophils
(isolated as described above) was extracted and reverse
transcribed as previously described [30]. Following the re-
verse transcription reaction, all samples were diluted 1:50
in ddH2O and subjected to real-time PCR analysis with
FastStart Universal Probe Master (Roche, cat#04913914001).
Ten picograms of gene-specific primers (IFN-β sense: 5′-
TCCATCATGAACAACAGGTG-3′; IFN-β antisense: 5′-
GACATTTCCGAA TGTTCGTC-3′; CCL3 sense: 5′-TG
TACCATGACACTCTGCAAC-3′; CCL3 antisense: 5′-
CA ACGATGAATTGGCGTGGAA-3′; TNF-α sense: 5′-
TCGGGGTGATCGGTCCCCAA-3′; TNF-α antisense:
5′-GGTGGTTTGCTACGACGTGGGC-3′; MMP9 sense:
5′-TCGCGTGGAT AAGGAGTTCT-3′; MMP9 antisense:
5′-CGGTTGAAGCAAAGAAGGAG-3′; CCL5 sense: 5′-
CCTCACCATATGGCTCGGACACC-3′; CCL5 antisense:
5′- GCGCGAGGGAGAGGTAG GCA-3′; Arg-1 sense: 5′-
CTCCAAGCCAAAGTCCTTAGAG-3′; Arg-1 antisense:
5′- GGAGCTGTCATTAG GGACATCA-3′) were used
in a total reaction volume of 15 μl. For all targets, the fol-
lowing cycling conditions were: 95°C for 10 minutes,
followed by 40 cycles each consisting of 95°C for 15 sec-
onds, 60°C for 30 seconds and 72°C for 45 seconds. In-
corporation of SYBR Green dye into the PCR products
was monitored using a Rotor Gene RG-3000 Real-time
PCR system (Roche). Pfaffl analysis method was used to
measure the relative quantity of gene expression [36]. The
reference gene, Gapdh (Gapdh sense: 5′-CAAGTATGAT
GACATCAAGAAGGTGG-3′; Gapdh antisense: 5′-GG
AAGAGTGGGAGTT GCTGTTG-3′) was selected based
on its stable expression in all cell populations analyzed.
Relative mRNA levels were expressed as relative expression
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CD11b+/Ly-6G+ neutrophils. All measurements were done
in duplicate from four independent sets of injections.
Statistical analysis
The significance values associated with the positivity for
CD3, Ly-6G (clone 1A8), NE, co-localization of s100a8
and NE and the formation of bone, lung or liver metas-
tases from breast cancer cells in mice depleted for Gr-1+
cells or Ly-6G+ cells versus isotype controls were calcu-
lated using a Student t test.
Results
Gene expression profiling reveals distinct expression
patterns associated with 4T1 subpopulations derived
from different metastatic sites
We previously reported the isolation of 4T1-derived
subpopulations explanted from primary breast tumors
(148, 152 and 154) [31] as well as in vivo selected cells
that grow aggressively in bone (590, 592 and 593) [29],
lung (526, 533 and 537) [31] or liver (2776, 2792 and
2869) [30] (Figure 1A). To identify mediators that contrib-
ute to general and/or organ-specific metastatic abilities of
breast cancer cells, we performed gene expression profil-
ing using Agilent whole mouse genome microarrays on
each of these cell populations (Figure 1B). This approach
yielded 395 differentially expressed genes (fold change: 2;
false discovery rate: 0.05; see Additional file 1), which,
when used to hierarchically cluster the cell populations,
could largely segregate them according to the site from
which they were derived (Figure 1C).
4T1-derived metastatic breast cancer populations possess
distinct chemokine profiles
We next subjected the 395 genes to Ingenuity Pathway
Analysis (IPA), which revealed 34 significantly affected
pathways (Table 1). Of these, a granulocyte adhesion and
diapedesis-associated gene signature was the most prom-
inent pathway affected in the various 4T1-derived ex-
plants. Intriguingly, other pathways implicating immune
cell responses such as IL8 signaling, antigen presentation
or leukocyte extravasation were also identified (Table 1).
These pathways are characterized by the differential ex-
pression of several common genes, including those encod-
ing chemokines (Table 1), which are known to induce
directed chemotaxis in responsive leukocyte populations.
To determine the repertoire of chemokines secreted by
the 4T1-derived breast cancer populations, we employed a
multiplex chemokine antibody array (Figure 2). Using this
approach, we found that CCL2 and CXCL2, which are
chemotactic for inflammatory monocytes and granulo-
cytes [37,38], respectively, were secreted at higher levels
by all metastasis-derived cell populations compared to pri-
mary tumor explants and the parental cell line (Figure 2).The bone- and lung-aggressive populations exhibited the
highest degree of variability in expression of many chemo-
kines; whereas the liver-metastatic populations were also
characterized by uniformly high levels of CXCL9 and
CCL9 (Figure 2), which are known to recruit T lympho-
cytes and neutrophils, respectively [39,40]. Collectively,
this data demonstrate that cell populations, selected for
their ability to metastasize to distant organs, are character-
ized by an increased production of chemokines and that
the pattern of secreted chemokines differs depending on
the metastatic site from which they were derived.
T lymphocytes are recruited to breast cancer liver and
lung metastases
Metastatic breast cancer cells expressed chemokines that
can direct the recruitment of T lymphocytes (CXCL9,
CCL2 or CX3CL1) [40-42]. Immunohistocytochemistry
staining with an antibody against a pan T cell marker
(CD3) revealed positivity in all samples examined
(Figure 3A,B). Indeed, CD3-positive staining was found
enriched in both lung and liver metastases compared to
bone metastases or primary tumors (Figure 3B). In
addition, CD3-positivity was higher in lung or liver metas-
tases compared to tissue adjacent (ADJ) to the metastases
or control (CTRL) samples that were devoid of lesions
(Figure 3B). However, while CD3-positive cells were found
throughout the lung lesions, about 2/3 of liver lesions re-
vealed increased abundance of CD3-positive cells at the
periphery of the metastatic lesions (Figure 3). These data
indicate that T lymphocyte recruitment is associated with
lung and liver metastases and localization differs depend-
ing on metastatic site.
A granulocytic infiltrate is recruited in breast
cancer-derived lung and liver metastases
Several chemokines that are known to recruit myeloid
cells (CCL2, CCL9, CXCL2), including monocytes and
neutrophils, were expressed by metastatic breast cancer
cells (Figure 2) [39,43]. We next extended our analysis
by performing immunohistocytochemical staining on
4T1-derived metastatic samples with a Ly-6G antibody
(clone 1A8). While some data suggests that Ly-6G can
be expressed on granulocytic MDSCs [44,45], multiple
studies suggest that Ly-6G serves as a neutrophil marker
[46-50]. Low to moderate Ly-6G staining was observed
in primary tumors and bone metastases. In contrast,
strong staining was observed in lung and liver metasta-
ses compared to control (CTRL) samples that were de-
void of lesions (Figure 4). Interestingly, while some
positive cells were found within the metastatic lesions
(TUMOR), the vast majority of positive cells were located
in tissue adjacent (ADJ) to the metastases (Figure 4). Strik-
ingly, a very high density of Ly-6G-positive cells was ob-
served in close proximity (PROX ADJ) of the lesions,
Figure 1 Gene expression profiling reveals distinct expression patterns associated with different metastatic 4T1 subpopulations.
(A) Schematic depicting 4T1-derived breast cancer cell populations isolated from distinct metastatic sites. (B) To identify candidate genes that
were differentially expressed among the isolated populations, each group (parental cell line and the explants derived from mammary fat pad (PE),
bone, lung and liver metastases) was individually compared to all the other groups. A two-fold change cutoff was determined and 395 differentially
expressed genes were selected using a nonparametric test coupled with a 5% false discovery rate. (C) A heatmap displaying the hierarchical clustering
of isolated 4T1-derived cell populations using the 395 differentially expressed genes. Red color indicates those genes that are highly expressed and
the green color denotes those genes that are underexpressed. The majority of cell populations clustered according to the site from which they were
derived.
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compared to more distal tissue (ADJ, Figure 4). These data
reveal a significant granulocytic component in liver metas-
tases formed by 4T1 liver-metastatic breast cancer cells.
We next confirmed these observations by staining the
metastatic samples with an antibody against NE as an
additional neutrophil marker (see Additional file 2)
[51,52]. In agreement with the Ly-6G staining, low to
moderate NE staining was observed in primary tumors
and bone metastases, while stronger NE staining wasdetected in lung and liver metastases compared to CTRL
tissues lacking metastatic lesions (see Additional file 2).
Moreover, NE positivity was mainly detected in tissue
adjacent to the lesions (PROX ADJ) with the most in-
tense staining localized immediately next to the liver
metastases (PROX ADJ) (see Additional file 2). Taken
together, our results demonstrate differential recruit-
ment of immune cells into distinct metastatic sites, with
high granulocyte and neutrophil positivity being de-
tected in bone marrow, lung tissue and liver tissue.
Table 1 Differentially affected pathways by Ingenuity Pathway Analysis
Ingenuity canonical pathways p-value Ratio Molecules
Granulocyte adhesion and diapedesis 4.94E-06 7.18E-02 VCAM1,SDC1,MMP3,MMP10,CLDN7,CCL5,CXCL5,IL18RAP,CXCL10,
ITGB2,MMP9,CLDN3,MMP19
Inhibition of matrix metalloproteases 3.54E-05 1.50E-01 SDC1,MMP3,RECK,MMP10,MMP9,MMP19
MMP19 hepatic fibrosis/hepatic stellate cell activation 8.91E-05 6.45E-02 02VCAM1,CTGF,FGFR1,PDGFRA,LBP,CCL5,PDGFC,MMP9,PGF,IL18RAP
Regulation of the epithelial-mesenchymal transition pathway 1.81E-04 5.61E-02 MAP2K6,CDH1,JAG2,WNT10B,ESRP2,FGFR1,PARD6G,JAG1,NOTCH1,
MMP9,CLDN3
Agranulocyte adhesion and diapedesis 2.09E-04 5.76E-02 CXCL10,ITGB2,VCAM1,MMP3,MMP10,CLDN7,CCL5,CXCL5,MMP9,
CLDN3,MMP19
HIF1alpha signaling 2.68E-04 7.14E-02 MMP3,MMP10,PDGFC,LDHA,MMP9,LDHB,PGF,MMP19
Antigen presentation pathway 3.05E-04 1.19E-01 B2M,PSMB9,HLA-B,PSMB8,TAP1
Bladder cancer signaling 5.99E-04 7.22E-02 CDH1,MMP3,MMP10,PDGFC,MMP9,PGF,MMP19
IL-8 signaling 9.59E-04 4.44E-02 ITGB2,GNB4,CDH1,ANGPT2,VCAM1,CCND2,MYL12B,PDGFC,
MMP9,PGF
Leukocyte extravasation signaling 1.48E-03 4.76E-02 ITGB2,VCAM1,EDIL3,MMP3,CD44,MMP10,CLDN7,MMP9,CLDN3,
MMP19
VDR/RXR activation 1.63E-03 6.82E-02 CXCL10,SPP1,GADD45A,SEMA3B,VDR,CCL5
Pyruvate fermentation to lactate 2.53E-03 2.22E-01 LDHA,LDHB
ILK signaling 3.47E-03 4.39E-02 MAP2K6,ITGB2,PARVB,CDH1,VIM,PDGFC,MMP9,DSP,PGF
Pathogenesis of multiple sclerosis 8.71E-03 2.00E-01 CXCL10,CCL5
Sphingosine-1-phosphate signaling 8.97E-03 4.88E-02 PLCD1,CASP12,CASP1,PDGFRA,CASP4,PDGFC
Axonal guidance signaling 1.04E-02 2.90E-02 WNT10B,BDNF,MMP10,ADAMTS9,PDGFC,SEMA4C,PGF,PLCD1,GNB4,
MYL12B,BMP7,SEMA3B,MMP9,SEMA7A
Atherosclerosis signaling 1.39E-02 4.35E-02 ITGB2,VCAM1,MMP3,S100A8,PDGFC,MMP9
Sorbitol degradation I 1.62E-02 2.00E-01 SORD
Asparagine biosynthesis I 1.62E-02 1.25E-01 ASNS
Alanine biosynthesis III 1.62E-02 3.33E-01 NFS1
Colorectal cancer metastasis signaling 1.73E-02 3.36E-02 GNB4,CDH1,WNT10B,MMP3,MMP10,PDGFC,MMP9,PGF,MMP19
p53 signaling 1.75E-02 4.63E-02 TP53INP1,CCND2,GADD45A,PLAGL1,SFN
Role of IL-17A in psoriasis 1.81E-02 1.43E-01 S100A8,CXCL5
Chondroitin sulfate degradation (metazoa) 2.09E-02 8.70E-02 CD44,HEXA
Human embryonic stem cell pluripotency 2.19E-02 3.73E-02 WNT10B,BDNF,FGFR1,PDGFRA,BMP7,PDGFC
Notch signaling 2.33E-02 6.98E-02 JAG2,JAG1,NOTCH1
Dermatan sulfate degradation (metazoa) 2.38E-02 8.70E-02 CD44,HEXA
Thyroid cancer signaling 2.66E-02 6.82E-02 CXCL10,CDH1,BDNF
Alanine degradation III 3.21E-02 1.67E-01 GPT2
Alanine biosynthesis II 3.21E-02 1.67E-01 GPT2
Formaldehyde oxidation II (glutathione-dependent) 3.21E-02 1.00E-01 ESD
Glutamine degradation I 3.21E-02 2.00E-01 GLS2
GADD45 signaling 4.09E-02 8.33E-02 CCND2,GADD45A
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ing upon the metastatic lesion in question.
Gr-1+ cell depletion differentially affects the formation of
bone, lung and liver metastases
Our data reveal a significant innate immune infiltrate in
soft tissue metastases. To examine whether monocytes/
macrophages or granulocytic cells present in theseinfiltrates can influence the metastatic abilities of the
4T1-derived subpopulations, we first assessed the ability
of 4T1 metastatic breast cancer cells to establish and
grow in mice depleted of monocytes/macrophages,
MDSCs, dendritic cells and neutrophils (Figure 5A).
Treatment of mice with anti-Ly-6C/Ly-6G antibodies
(clone RB6-8C5) is a well-established method that results
in the depletion of approximately 97% of circulating
Figure 2 4T1-derived breast cancer populations possess distinct and overlapping chemokine profiles. A heatmap representing the
secreted levels of 25 chemokines measured using a chemokine array. The chemokines are grouped based on the immune cell types that they are
known to recruit (multiple immune cell types, macrophages and/or lymphocytes, T lymphocytes and/or neutrophils, macrophages, T lymphocytes
or neutrophils). Red color indicates chemokines that are highly expressed and the blue color denotes chemokines that are underexpressed.
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chemical staining results, depletion of Ly-6C+/Ly-6G+
cells had no major effect on the overall bone metastatic
burden, as measured by μCT analysis, following left car-
diac ventricle injection of bone-aggressive breast cancer
cells (Figure 5B). We also interrogated whether Ly-6C+/
Ly-6G+ cells support lung and liver breast cancer metasta-
sis given the significant enrichment of these immune cells
into (lung) or surrounding (liver) metastatic nodules. Sur-
prisingly, depletion of Ly-6C+/Ly-6G+ cells also had no ef-
fect on the establishment of lung metastasis following
intravenous injection of lung-aggressive cells (Figure 5C).
In contrast, following splenic injection of the liver-
aggressive 4T1 subpopulations, Ly-6C+/Ly-6G+-depleted
mice showed markedly reduced tumor burden in the liverwhen compared to their control counterparts (Figure 5D).
Indeed, lesions formed in control mice occupied 2.36
times less of the liver area when compared to control mice
(Figure 5D).
The use of anti-Ly-6C/Ly-6G antibodies in the previ-
ous depletion experiment will remove both monocytes/
macrophages and granulocytes [21,49,50,55,56]. To nar-
row down the critical cell population required for the ef-
ficient formation of liver metastases, we next examined
the ability of the liver-aggressive 4T1 subpopulations to
establish and grow in the liver of mice depleted using
anti-Ly-6G antibodies (clone 1A8) (Figure 6A). Indeed,
Ly-6G has been shown to be specifically expressed by
granulocytes or polymorphonuclear (PMN) MDSCs [44].
The use of anti-Ly-6G antibodies (clone 1A8) has been
Figure 3 T lymphocytes are recruited to liver and lung metastases from breast cancer. Paraffin-embedded sections from primary breast
tumors, bone specimens, lung specimens and liver specimens obtained following experimental metastasis assays were subjected to
immunohistochemical staining with anti-CD3 antibodies. (A) Representative images from 20X, 40X magnifications for each site are shown. 40X
images were taken at the margin of the lesions (40X margin) and in more distal regions (40X adj.). Scale bar represents 40 μm (20X) or 20 μm
(40X) and applies to all panels of the same magnification. (B) Positivity of CD3 staining (expressed as a ratio of positive pixels over the total pixels
per field) quantified inside lesions (TUMOR), in the adjacent tissue (ADJ) or in control (CTRL) samples without any lesions. Lymphocyte T expression
and recruitment is mostly associated with lung or liver metastasis (*: P <0.001).
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neutrophils [21,49,55-59]. Immunohistochemical stain-
ing using anti-Ly-6G antibodies revealed a 2.7-fold de-
crease in neutrophils that were recruited to the liver at
the experimental endpoint (Figure 6B). As observed
with mice depleted of Ly-6C+/Ly-6G+ cells, depletion of
only Ly-6G+ cells resulted in decreased tumor burden in
the liver following splenic injection, resulting in a 2.92-
fold reduction in the liver-metastatic area/liver tissue
area when compared to mice treated with the isotype
control antibodies (Figure 6C). Together, these data
demonstrate that the recruitment of Ly-6G+ granulo-
cytes, of which neutrophils comprise a significant com-
ponent, is functionally involved in breast cancer cell
metastasis to specific sites, being dispensable for the for-
mation of bone and lung metastases but playing an im-
portant positive role in the colonization and growth of
liver metastases.Neutrophil recruitment persists at the lesion margins
during progression of breast cancer-derived liver
metastases
Given that the tumor microenvironment evolves as tu-
mors progress [60], we assessed if the observed recruit-
ment of neutrophils changed during hepatic metastasis
progression. To do so, we examined liver metastases
samples isolated from mice either at early (10 days) or
late (21 days) time points post splenic injection with
2776 or 2792 liver-aggressive cell lines. We performed
immunohistofluorescence using S100a8 as a marker
whose expression is restricted to macrophages, MDSCs
and neutrophils [61-64] coupled with NE as a marker for
neutrophils [51,52]. We observed a clear increase in the
total numbers of s100a8+ (Figure 7A) and NE+ (Figure 7B)
cells within the lesions and in the distal liver, with minimal
changes at the margin of the liver metastases (Figure 7A,B).
However, the proportion of the s100a8+ infiltrate that is
Figure 4 Ly-6G+ cells are recruited in breast cancer-derived lung and liver metastases. Paraffin-embedded sections from primary breast
tumors, bone metastases, lung metastases and liver metastases were obtained following experimental metastasis assays and subjected to
immunohistochemical staining with anti-Ly-6G antibodies. (A) Representative images from 20X and 40X magnifications for each metastatic site are
shown. 40X images were taken either at the margin of the lesions (40X margin) or in regions distal to the metastatic lesion (40X adj.). (B) Positivity of
Ly-6G staining (expressed as a ratio of positive pixels over the total pixels per field) was quantified within the metastatic lesions (TUMOR), in close
proximity to the metastatic lesion (PROX ADJ), in the tissue adjacent (ADJ) to the metastases or in control (CTRL) samples without any metastatic lesions.
Increased recruitment of Ly-6G+ cells was observed in close proximity to hepatic metastases (*: liver tumor vs. liver adj., P <0.001; liver adj. vs. liver prox.
Adj., P <0.001; lung tumor vs. lung adj., P <0.001). Scale bar represents 40 μm (20X) or 20 μm (40X) and applies to all panels of the same magnification.
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metastatic lesions (TUMOR; Figure 7C, see Additional
file 3) and in distal tissue (DISTAL; Figure 7C), suggesting
the late recruitment of additional innate immune cell pop-
ulations. Interestingly, no major changes in the percentage
of neutrophils were observed at the margin surrounding
hepatic metastases (MARGIN, Figure 7C, see Additional
file 3). Together, our results suggest that recruitment of
NE+ neutrophils at the invasion front of liver metastasis is
an early event that is maintained during liver metastases
progression. The initial infiltration of neutrophils is followed
by a subsequent influx of s100a8+ cells that may include
macrophages, MDSCs and additional granulocytic cells.
N2-polarized neutrophil recruitment increases at the lesion
margins during progression of breast cancer-derived liver
metastases
In order to characterize the phenotype of neutrophils
during liver metastasis development, we isolated thesecells based on CD11b and Ly-6G expression, which are
routinely used in the literature as neutrophil markers
[21,44,48,55,58,65]. Liver-infiltrating neutrophils were
purified from mice at early (7 days) or late (14 days) time
points following splenic injection with the 2776 liver-
aggressive cell line (Figure 8A). To study the phenotypic
changes that occurred in the neutrophils during liver me-
tastasis progression, we performed real-time quantitative
PCR (qPCR) to monitor the expression of genes previously
reported to differentiate N1- and N2-polarized neutrophils
[60,66]. With the exception of TNF-α, we did not detect
significant differences in the expression of molecules re-
ported to be preferentially expressed in N1-polarized neu-
trophils, such as IFN-β or CCL3, when comparing early
and late isolated liver metastasis-associated neutrophils
(Figure 8B). However, we did observe an increase in the
expression of molecules reported to be preferentially
expressed in N2-polarized neutrophils, such as MMP9,
CCL5 or Arginase 1, which were increased during liver
Figure 5 Depletion of Gr-1+ (Ly-6C/Ly-6G) cells differentially affects the establishment and growth of bone, lung and liver metastases.
(A) Schematic depicting the experimental protocol for depletion of Gr-1+ cells. (B) The degree of osteolytic bone destruction in the hindlimbs of
mice treated with anti-Gr1 and isotype control antibodies was quantified by in vivo micro-computed. tomography (μCT) imaging. Bone volume of
defined regions of the proximal tibia is shown following cardiac injection of 593 bone-aggressive cells. No difference was observed when comparing
bone volumes between the two populations. Representative images of bone reconstructions are shown. (C) Quantification of the tumor burden
(tumor area/tissue area) within the lung following tail vein injection of 526 lung-aggressive cells. No statistical difference in lung metastatic burden was
observed when the isotype control cohort was compared with Gr-1+-depleted cohort. (D) Quantification of the tumor burden (tumor area/tissue area)
within the cardiac liver lobe following splenic injection of 2776 liver-aggressive cells. Statistically significant decreases in liver-metastatic burden were
observed when the isotype control cohort was compared with the Gr-1-depleted cohort (P = 0.012). Hematoxylin and eosin (H&E) images of the lung
or cardiac liver lobe are shown for mice injected with each of the indicated cell populations and treated with isotype control or anti-Gr1 antibodies.
Dotted lines circumscribe breast cancer metastatic lesions within the liver. Scale bar represents 2 mm and applies to all panels. IP: intraperitoneal
injection; ns: not statistically significant.
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spectively) (Figure 8C). These data suggest that some neu-
trophils have undergone a putative transition to an N2
phenotype while others retain markers suggestive of an
N1 phenotype. Such a result could indicate that neutrophilphenotypes could be influenced by their location within
the liver and their proximity to the metastatic lesions.
Since our results highlighted the recruitment of neu-
trophils at the invasive front of liver metastases during
liver metastasis progression (Figure 7), we next assessed
AB
Figure 6 Ly-6G+ cell depletion decreases the establishment and growth of liver metastases. (A) Schematic depicting the experimental
protocol for depletion of Ly-6G+ cells. (B) Paraffin-embedded liver sections were obtained following completion of the experimental metastasis
assays and subjected to immunohistochemical staining with anti-Ly-6G antibodies. Statistically significant decreases in Ly-6G+ cells that infiltrate
the liver were observed when the neutrophil-depleted cohort was compared with the isotype control cohort (P = 0.045). Representative images
of Ly-6G-stained liver sections from each cohort. (C) Quantification of the tumor burden (tumor area/tissue area) within the cardiac liver lobe
following splenic injection of 2776 liver-aggressive cells. Statistically significant decreases in liver-metastatic burden were observed when the
isotype control cohort was compared with the neutrophil-depleted cohort (P = 0.031). Representative images of hematoxylin and eosin (H&E)-
stained liver sections exhibiting the liver-metastatic burden in each cohort. Dotted lines circumscribe breast cancer metastatic lesions within the
liver. Scale bar represents 2 mm and applies to all panels. IP: intraperitoneal injection.
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invasion front compared to more distal regions. Thus, we
examined liver metastases isolated from mice either at
early (7 days) or late (14 days) time points post splenic in-
jection with 2776 liver-aggressive cell line and performed
immunofluorescence using CD11b and Ly-6G (clone 1A8)
as markers for neutrophils coupled with MMP9 as a
marker associated with N2-polarized neutrophils. We ob-
served a clear increase in the percentage of N2-polarized
neutrophils (defined as CD11b+/Ly-6G+/MMP9+) at the
invasive front of liver metastases compared to those sit-
uated in regions distal to the metastatic lesions (Table 2,
see Additional files 4 and 5). Moreover, we observed a
correlation between the percentage of N2-polarized
neutrophils and the liver-metastatic burden (Table 2).
Taken together, our results support the presence of a
mixed population of neutrophils during breast cancer
liver metastasis development and demonstrate that neu-
trophils become more N2 polarized as liver metastasis
progresses and a greater fraction of neutrophils adopt
an N2 phenotype when they are located close to the
liver-metastatic lesions.
Discussion
We have employed 4T1 breast cancer subpopulations,
derived from primary mammary tumors or bone, lung
and liver metastases, to identify potential mediators of
general or organ-specific breast cancer metastasis. Ingenu-
ity Pathways Analysis highlighted differential expressionof genes involved in several pathways implicating immune
responses. This observation is not surprising considering
that leukocyte infiltrates are detected in most tumors and
are often associated with poor prognosis [2,67]. Distinct
chemokines secreted by cancer cells are responsible for
recruiting immune cells to the growing tumor, and the
composition of this infiltrate can change during cancer
progression [68]. Our results reveal that secretion of dis-
tinct and overlapping chemokines characterizes breast
cancer cell populations isolated from different metastatic
sites. Of these, CCL2 and CXCL2 were uniformly elevated
in all of the metastatic populations, regardless of origin.
CCL2 is expressed in various cancers, including breast tu-
mors, and is considered a tumor-derived chemotactic fac-
tor for diverse immune cell types [9]. CCL2 production,
by the tumor and/or cells within the stromal microen-
vironment, recruits Gr-1+ cells to breast cancer lung me-
tastases and leads to the subsequent recruitment of
metastasis-associated macrophages [38]. Moreover, it has
been shown that CCL2 expression by colorectal cancer
cells can recruit Gr-1+ cells, which are important for the
establishment and growth of colorectal liver metastases
[69,70]. Conversely, CCL2 has been implicated in the re-
cruitment of neutrophils into lungs of mice bearing breast
cancer lung metastases, which eliminate disseminated
cancer cells and diminish the formation of metastases
[71]. Thus, the ultimate consequence of CCL2-mediated
immune cell recruitment, either pro- or anti-metastatic,
will be highly context dependent.
Figure 7 Neutrophils are recruited to early lesions and are maintained at the margin of liver metastases over time. Paraffin-embedded
sections from liver metastases were collected at early (1.5 week) or late (3 weeks) time points following experimental metastasis assays and
subjected to immunohistofluorescence staining with anti-S100a8 (red) or anti-neutrophil elastase (NE) (green) antibodies. The number of S100a8-
positive cells (A) or NE-positive cells (B) per field was quantified. (C) Positivity of neutrophil staining (expressed as a percentage of S100a8 and NE
double-positive cells over the total number of S100a8-positive cells) was quantified within each region of interest. While the number of s100a8-
and NE-positive cells increased during tumor progression (s100a8 distal early vs. distal late, P <0.001; NE distal early vs. distal late, P = 0.021; s100a8
tumor early vs. tumor late, P <0.001; NE tumor early vs. tumor late, P <0.001), a decrease in the proportion of neutrophils comprising the s100a8+
infiltrate was routinely observed in the tumor or the distal region as tumor progressed (distal early vs. distal late, P = 0.019; tumor early vs. tumor
late, P = 0.006). In contrast, no changes were observed in the margin of the lesions.
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played by CXCL2 in breast cancer metastasis. Recently,
it was shown that breast cancer cells expressing elevated
levels of CXCL1 and CXCL2 induce the recruitment of
MDSCs into the primary mammary tumor. These infil-
trating immune cells secrete s100a8/s100a9 that aug-
ments breast cancer survival during metastasis and in
response to chemotherapy. The use of CXCL1/2 recep-
tor inhibitors, combined with chemotherapy, resulted in
reduced lung metastasis using MDA-MB-231 breast can-
cer cells [72]. These observations indicate that meta-
static cancer cells secrete cytokines, such as CCL2 and
CXCL2, to recruit innate immune cells that drive metas-
tasis formation.
Interestingly, CCL9 and CX3CL1 were strongly and uni-
formly elevated in the liver-metastatic breast cancer cells.
CCL9 (and CCL15) secreted by mouse and human colon
cancer cells has been shown to recruit immature myeloid
cells (iMCs), which produce matrix metalloproteinasesMMP2 and MMP9 required for successful colonization of
the liver [73]. Similarly, using a TGFβ signaling-deficient
model of colon cancer, it was shown that increased num-
bers of iMCs are recruited from the bone marrow to the
invasive front of liver metastases, in response to a gradient
of CCL9 [74]. It has also been recently shown that
CX3CR1, the receptor for CX3CL1, is functionally re-
quired in TAMs to support angiogenesis and efficient for-
mation of colon cancer liver metastases [75]. Together,
these observations are consistent with the selection for el-
evated expression of CCL9 and CX3CL1 in breast cancer
cells that are metastatic to the liver.
Our immunohistochemical staining revealed that a sig-
nificant proportion of cells detected in metastatic tissues
are neutrophils, as determined by Ly-6G or NE staining.
The enrichment of neutrophils at early stages and the
recruitment of additional innate immune cells (s100a8+)
at later time points was further confirmed by our im-
munofluorescence data. Interestingly, s100a8 and s100a9,
AB C
Figure 8 N2-polarized neutrophils are recruited to the invasive front of liver metastases over time. (A) Schematic depicting the
experimental protocol to isolate neutrophils from metastasis-bearing livers. (B) Quantitative real-time PCR analysis was performed for IFN-β, CCL3
and TNF-α as markers for anti-tumorigenic (N1)-polarized neutrophils, normalized to total Gapdh levels, in neutrophils isolated from early (7 days)
or late (14 days) time points post splenic injection with the 2776 liver-aggressive cell line. The data is depicted as fold expression relative to early
time point and is representative of four independent experiments performed in triplicate. (C) Quantitative real-time PCR analysis was performed
for MMP9, CCL5 and Arginase 1 as markers for pro-tumorigenic (N2)-polarized neutrophils, normalized to total Gapdh levels, in neutrophils isolated
from early or late time points post splenic injection with the 2776 liver-aggressive cell line. The data is depicted as fold expression relative to early
time point and is representative of four independent experiments performed in triplicate.
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moattractants for the subsequent recruitment of macro-
phages and activated monocytes [76,77]. We observed
that the proportion of NE+ neutrophils within the innate
immune infiltrate diminished during the growth of liver
metastases (within the lesions and in distal liver tissue),
but were retained at the invasive front of the growing me-
tastases. Our data reveal that neutrophils become increas-
ingly polarized toward an N2 phenotype as the liver
metastases progress. Furthermore, we demonstrate that
neutrophils situated at the margin of the liver-metastatic
lesions are enriched for ‘N2’ polarized phenotype com-
pared to those located distal to the metastases. The latter
observation is in agreement with previous findings that
TANs, in the context of mesothelioma, acquire a more
pro-tumorigenic phenotype as the tumors progress [60].
Thus, it is possible that infiltrating neutrophils, and the
subsequent recruitment of MDSCs, are needed for the
progression of liver metastases by dampening anti-tumor
immune responses and promoting a pro-angiogenic
microenvironment [78].
We demonstrate that depletion of Gr-1+ cells in mice
differentially affects the metastatic potential of well-characterized 4T1 breast cancer cell populations [29-31].
Previous reports have shown that depletion experiments,
using Gr-1-specific (Ly-6C/Ly-6G) antibodies, inhibit
tumor growth, reduce endothelial cell recruitment to tu-
mors and limit metastasis, in part, by restoring immune
surveillance [28,79-83]. In contrast, it has been reported,
using similar Ly-6G-specific depletion experiments, that
removal of neutrophils can promote the formation of lung
metastases [71]. We did not observe any positive or nega-
tive effects on the formation of lung or bone metastases
following Ly-6C/Ly-6G-mediated depletion. In contrast,
depletion of either Ly-6C+/Ly-6G+ cells or specifically Ly-
6G+ cells reduced the ability of liver-aggressive breast can-
cer populations to form hepatic metastases, supporting a
pro-metastatic role for neutrophils in this process. These
data argue that, despite a complex innate immune infil-
trate surrounding the emerging liver metastases, it is the
neutrophil component (Ly-6G+ cells) that plays a critical
functional role in the establishment and growth of 4T1-
derived liver metastases. An emerging body of literature
supports a role for MDSCs and neutrophils in specifically
promoting liver metastasis [78]. Colorectal cancer liver
metastases are characterized by the infiltration of bone
Table 2 N2-polarized neutrophils are recruited at the
invasive front of breast liver metastases over time
D7
Location 0 <metastatic lesion area/liver area (%) <1.79
% N2 neutrophilsa Error P value
Distal 60.84 +/− 9.39
Invasive front 90.19 +/− 6.04 <0.00001
D14
Location Low metastatic burden
2.16 <metastatic lesion area/liver area (%) <4.19
% N2 neutrophilsa Error P value
Distal 79.58 +/− 5.93
Invasive front 94.92 +/− 3.56 <0.0001
D14
Location High metastatic burden
13.62 <metastatic lesion area/liver area (%) <54.12
% N2 neutrophilsa Error P value
Distal 88.21 +/− 3.53
Invasive front 93.63 +/− 2.80 0.003
aOCT-embedded sections from liver metastases were collected either 7 days
(D7) or 14 days (D14) following splenic injection of breast cancer cells and
subjected to immunohistofluorescence staining with anti-Ly-6G (cyan), MMP9
(red) or Cd11b (green) antibodies. The percentage of pro-tumorigenic (N2)-
polarized neutrophils (Cd11b+/Ly-6G+/MMP9+) out of the total number of
neutrophils (Cd11b+/Ly-6G+) was assessed either at the invasive front of the
metastatic lesions or in regions distal to the metastases (distal). Representative
images can be found in Additional files 3 and 4.
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CCL2 secreted by CRC cells [69,70].
Roles specific to neutrophils and liver metastasis are
also emerging. Indeed, neutrophils have been implicated
in facilitating tumor cell extravasation. In the presence
of inflammatory stimuli, neutrophils have been shown to
adhere to activated sinusoidal endothelium and serve as
a bridge to capture circulating tumor cells to promote
seeding within the liver [20,84,85]. In the context of sys-
temic inflammation, administration of a NE inhibitor
decreased the liver-metastatic burden following injection
of lung carcinoma cells. In this study, neutrophils were
stimulated to undergo a process called NETosis, which is
the expulsion of condensed chromatin that forms extra-
cellular nets, caused the entrapment of circulating tumor
cells and enhanced the formation of liver metastases [19].
These data argue that neutrophils perform metastasis-
promoting functions immediately upon infiltration into
the metastatic site. This idea is challenged by studies that
show neutrophils recruited to the lung can facilitate clear-
ance of disseminated tumor cells, resulting in a reduction
in lung metastasis [71]. This concept was reinforced by
the studies demonstrating that early recruitment of neu-
trophils impaired the growth of mesothelioma or Lewis
Lung carcinomas via cytotoxic anti-tumor effects (N1phenotype). Subsequently, tumor-derived factors polarized
neutrophils toward a pro-tumorigenic (N2 phenotype) in
response to tumor-derived factors [60]. Our data suggest
that within growing liver metastases, infiltrating neutro-
phils progressively adopt an N2 phenotype as the lesions
grow and that the greatest concentration of N2 neutro-
phils resides immediately at the margin of the metastatic
lesions.
Conclusions
Our studies highlight the multifaceted role played by in-
nate immune cells, especially the Ly-6G+ component, in
regulating the spread of breast cancer cells to specific or-
gans, such as the liver. The role of neutrophils is becom-
ing increasingly important in light of clinical studies that
indicate the presence of neutrophil markers or elevated
neutrophil to lymphocyte ratios are associated with poor
clinical outcomes in breast cancer patients [86,87].
Additional files
Additional file 1: List of 395 differentially expressed genes. The table
contains a list of 395 genes that are differentially expressed between the
distinct 4T1-derived metastatic explant populations (bone, lung and liver).
Additional file 2: Neutrophils are recruited to breast cancer-derived
lung and liver metastases. Paraffin-embedded sections from primary
breast tumors, bone, lung and liver metastases were obtained following
experimental metastasis assays and subjected to immunohistochemical
staining with anti-neutrophil elastase (NE) antibodies. (A) Representative
images from 20X and 40X magnifications for each metastatic site are
shown. 40X images were taken either at the margin of the metastatic
lesions (40X margin) or in regions distal to the metastases (40X adj.).
(B) Positivity of NE staining (expressed as a ratio of positive pixels over
the total pixels per field) was quantified within the metastatic lesions
(TUMOR), in close proximity of the metastases (PROX ADJ), in tissue
adjacent (ADJ) to the metastatic lesions or in control (CTRL) samples
lacking breast cancer metastases. Increased recruitment of NE+ cells
proximal to liver metastases was routinely observed (*: liver tumor vs. liver
adj., P = 0.002; liver adj. vs. liver prox. Adj., P <0.001; lung tumor vs. lung
adj., P <0.001). Scale bar represents 40 μm (20X) or 20 μm (40X) and
applies to all panels of the same magnification.
Additional file 3: Neutrophils are recruited to early lesions and are
maintained at the margin of liver metastases over time. Paraffin-
embedded sections from liver metastases were collected at early
(1.5 weeks) or late (3 weeks) time points following splenic injection of
breast cancer cells and subjected to immunohistofluorescence staining
with anti-S100a8 (red) or anti-neutrophil elastase (green) antibodies.
Representative images captured at 63X magnification for each time point
are shown. Images were taken either within the metastatic lesions
(tumor), at the margin of the metastatic lesions (margin) or in regions
distal to the metastases (distal). Scale bar represents 50 μm and applies
to all panels.
Additional file 4: N2-polarized neutrophils are recruited at the
invasive front of breast liver metastases. OCT-embedded sections
from liver samples collected 1 week following splenic injection of breast
cancer cells were subjected to immunohistofluorescence staining with
anti-Ly-6G (cyan), MMP9 (red) or Cd11b (green) antibodies. Representative
images captured at 63X magnification for each time point are shown.
Images were taken either at the invasive front of the metastatic lesions or in
regions distal to the metastases (distal). Arrows: neutrophils (Cd11b+/Ly-6G+);
Arrowheads: pro-tumorigenic (N2)-polarized neutrophils (Cd11b+/Ly-6G+/
MMP9+). Dotted lines circumscribe breast cancer metastatic lesions within
the liver. Scale bar represents 50 μm and applies to all panels.
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invasive front of breast liver metastases. OCT-embedded sections
from livers with a low metastatic burden were collected at 2 weeks
following splenic injection of breast cancer cells and subjected to
immunohistofluorescence staining with anti-Ly-6G (cyan), MMP9 (red) or
Cd11b (green) antibodies. Representative images captured at 63X
magnification for each time point are shown. Images were taken either
at the invasive front of the metastatic lesions or in regions distal to the
metastases (distal). Arrows: neutrophils (Cd11b+/Ly-6G+); Arrowheads:
pro-tumorigenic (N2)-polarized neutrophils (Cd11b+/Ly-6G+/MMP9+).
Dotted lines circumscribe breast cancer metastatic lesions within the liver.
Scale bar represents 50 μm and applies to all panels.
Abbreviations
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iMCs: immature myeloid cells; i.p.: intraperitoneal; IPA: ingenuity pathway
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